Deregulation on joint, commissioned bioequivalence testing stirs debate

The government’s plan to deregulate the joint, commissioned bioequivalence testing has stirred up concerns among drug companies.

They fear that the new plan could not only slash their profits amid entry of too many players, but push many marginal companies out of business. Many small companies are reported to have already started looking to big firms for merger deals.

The plan, if careful...